1. Home
  2. SLNG vs SKYE Comparison

SLNG vs SKYE Comparison

Compare SLNG & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stabilis Solutions Inc.

SLNG

Stabilis Solutions Inc.

HOLD

Current Price

$4.27

Market Cap

92.0M

Sector

Utilities

ML Signal

HOLD

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

HOLD

Current Price

$1.13

Market Cap

44.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLNG
SKYE
Founded
2013
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Oil/Gas Transmission
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
92.0M
44.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SLNG
SKYE
Price
$4.27
$1.13
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
5
Target Price
$10.00
$14.75
AVG Volume (30 Days)
6.4K
567.0K
Earning Date
02-24-2026
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.05
N/A
Revenue
$72,270,000.00
N/A
Revenue This Year
$7.02
N/A
Revenue Next Year
$7.68
N/A
P/E Ratio
$81.41
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.29
$0.68
52 Week High
$8.28
$5.75

Technical Indicators

Market Signals
Indicator
SLNG
SKYE
Relative Strength Index (RSI) 49.25 54.59
Support Level $4.21 $0.68
Resistance Level $4.65 $0.95
Average True Range (ATR) 0.27 0.11
MACD -0.01 0.04
Stochastic Oscillator 55.56 85.49

Price Performance

Historical Comparison
SLNG
SKYE

About SLNG Stabilis Solutions Inc.

Stabilis Solutions Inc is an energy transition company that provides turnkey clean energy production, storage, transportation, and fueling solutions using liquefied natural gas (LNG) to multiple end markets. The company provides LNG solutions to customers in diverse end markets, including aerospace, agriculture, energy, industrials, marine bunkering, mining, pipeline, remote power, and utility markets. It generates revenue by selling and delivering LNG to its customers, renting cryogenic equipment, and providing engineering and field support services. It has a geographical presence in the United States and Mexico.

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: